$106.62
1.94% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US53220K5048
Symbol
LGND

Ligand Pharmaceuticals Incorporated Stock price

$108.73
-3.45 3.08% 1M
+8.78 8.78% 6M
+1.58 1.47% YTD
+35.52 48.52% 1Y
+37.83 53.37% 3Y
+64.85 147.80% 5Y
+61.88 132.09% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+3.91 3.73%
ISIN
US53220K5048
Symbol
LGND
Sector
Industry

Key metrics

Market capitalization $2.09b
Enterprise Value $1.84b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 19.46
EV/Sales (TTM) EV/Sales 11.04
P/S ratio (TTM) P/S ratio 12.53
P/B ratio (TTM) P/B ratio 2.50
Revenue growth (TTM) Revenue growth 27.28%
Revenue (TTM) Revenue $167.13m
EBIT (operating result TTM) EBIT $23.02m
Free Cash Flow (TTM) Free Cash Flow $94.80m
Cash position $256.17m
EPS (TTM) EPS $-0.15
P/E forward 46.79
P/S forward 10.94
EV/Sales forward 9.64
Short interest 6.81%
Show more

Is Ligand Pharmaceuticals Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Ligand Pharmaceuticals Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

Buy
100%

Financial data from Ligand Pharmaceuticals Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
167 167
27% 27%
100%
- Direct Costs 44 44
2% 2%
26%
123 123
40% 40%
74%
- Selling and Administrative Expenses 41 41
168% 168%
25%
- Research and Development Expense 21 21
16% 16%
13%
60 60
28% 28%
36%
- Depreciation and Amortization 37 37
0% 0%
22%
EBIT (Operating Income) EBIT 23 23
134% 134%
14%
Net Profit -4.03 -4.03
108% 108%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Ligand Pharmaceuticals Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ligand Pharmaceuticals Incorporated Stock News

Neutral
GlobeNewsWire
about one month ago
JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami).
Neutral
Seeking Alpha
about one month ago
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - CEO Paul Hadden - Senior Vice President of Investments and Business Development Tavo Espinoza - Chief Financial Officer Lauren Hay - Vice President of Strategic Planning and Investme...
Neutral
GlobeNewsWire
about one month ago
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla.
More Ligand Pharmaceuticals Incorporated News

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Head office United States
CEO Todd Davis
Employees 68
Founded 1987
Website www.ligand.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today